Results 241 to 250 of about 325,525 (350)

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

CENPF Overexpression Induced by HBV Infection Facilitates the G1/S Cell Cycle Transition of Hepatocellular Carcinoma Cells via MYC Pathway. [PDF]

J Hepatocell Carcinoma
Qi S, Zhou D, Chen S, Ouyang Q, Wu LN, Tang H, Li X, Li Y, Zi H, He P, Wang X, Ou X, Long J, Sun LY, Huang J.   +14 more
europepmc   +1 more source

Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.

Gastroenterology, 2016
Yuchen Xia, Daniela Stadler, J. Lucifora, F. Reisinger, D. Webb, M. Hösel, T. Michler, K. Wisskirchen, Xiaoming Cheng, Ke Zhang, Wen-Min Chou, J. Wettengel, A. Malo, F. Bohne, D. Hoffmann, F. Eyer, R. Thimme, C. Falk, W. Thasler, M. Heikenwalder, U. Protzer   +20 more
semanticscholar   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, EarlyView.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source

Knowledge, Attitudes, Practices, and Associated Factors of Healthcare Workers Toward Hepatitis B Post-Exposure Prophylaxis in Ethiopia: A Cross-Sectional Study. [PDF]

Health Sci Rep
Aligaz EM, Markos Z, Zegeye ST, Bayable SD.   +3 more
europepmc   +1 more source

An overview of consent requirements for HIV and viral hepatitis B and C testing in Europe

HIV Medicine, EarlyView.
Abstract Background Complicated consent procedures for bloodborne virus (HIV, HBV and HCV) testing present barriers to implementation, particularly in non‐specialist healthcare settings. European and global guidelines no longer recommend written consent. An overview of testing consent requirements in Europe is lacking. Methods An online survey on legal
Annemarie Rinder Stengaard, Ann K. Sullivan, Daniel Simões, Josephine Diderichsen, Dorthe Raben, Jürgen K. Rockstroh, on behalf of the EuroTEST Steering Committee, Ann K Sullivan, Ben Collins, Brian Gazzard, Carlos Mejia, Cary James, Casper Rokx, Daniela Rojas Castro, Deniz Gökengin, Ferenc Bagyinszky, Francesco Negro, Igor Karpov, Irith De Baetselier, Jack Lambert, Jens D. Lundgren, Johanna Brännström, Jordi Casabona, Jürgen Rockstroh, Olesia Murha, Lella Cosmaro, Liudmyla Maistat, Loreta Kondili, Magnus Unemo, Maria Prins, Michael Rayment, Milosz Parczewski, Mojca Matičič, Nicoletta Policek, Nikos Dedes, Nino Tsereteli, Olga Grozdetska, Sara Croxford, Tom Platteau, Valerie Delpech, Yazdan Yazdanpanah, Anastasia Pharris, Stela Bivol, Thomas Seyler   +43 more
wiley   +1 more source

Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination. [PDF]

Vaccines (Basel)
Su J, Kosinska AD, Miko S, Ates Öz E, Laer DV, Kimpel J, Protzer U.   +6 more
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection. [PDF]

Microbiol Spectr
Yan H, Li Y, Liu C, Guo H, Liu Y, Wang H, Ge X, Zhang Z, Ju B.   +8 more
europepmc   +1 more source